Eli Lilly has announced promising clinical trial results for orforglipron, a daily pill for treating obesity and diabetes. This experimental drug belongs to the GLP-1 class, popular for weight loss but traditionally administered via weekly injections. If orforglipron proves effective in pill form, it could significantly expand access to such treatments. Eli Lilly plans to seek regulatory approval for weight loss indications later this year and for diabetes early next year. The FDA review process could take several months. Analysts predict the drug might become available in the U.S. by the second half of next year if trials and reviews proceed smoothly.
— new from The New York Times